“Vascular mimicry” observed in mice could be helping tumors evade anti-angiogenesis drugs
Cold Spring Harbor, NY — Imitation may be the sincerest form of flattery, but it can also have deadly consequences, at least when it comes to tumor cells.
A team of researchers from Cold Spring Harbor Laboratory (CSHL) and the CRUK Cambridge Institute at the University of Cambridge has shown in a mouse model that the ability of tumor cells to form tubular networks that mimic blood vessels can help drive metastasis, the spread of breast cancer to different sites in the body.
The team has discovered that two genes, Serpine2 and Slpi, help direct a phenomenon known as “vascular mimicry.” Vascular mimicry involves the formation of tubular networks made of tumor cells, which can transport blood to different parts of a tumor. These tubular networks are thought to be able to provide the tumor with oxygen and nutrients, thus mimicking the role of blood vessels. The researchers found that reducing the expression of Serpine2 or Slpi in a primary tumor reduced vascular mimicry in the tumor.
The team was led by CSHL Professor and HHMI Investigator Gregory Hannon, who is also a Professor at the University of Cambridge and by Simon Knott, a research investigator at CSHL. CSHL postdoctoral investigator Elvin Wagenblast is the first author of the report announcing the findings today in Nature.
Vascular mimicry appears also to allow tumor cells greater access to the bloodstream, from where they can spread to other sites in the body. Overexpressing Serpine2 or Slpi led to more tumor cells being able to get into the blood. These same genes have previously been found to be overexpressed in human patients whose cancers had spread to their lungs.
“It’s very neat to watch and see cells evolve to have these capacities,” says Knott. “But on the other hand it’s really scary to think that these cells are sitting there in people doing this.”
The fact that the products of the genes in question, Serpine2 and Slpi, are secreted proteins means that they are both potentially targetable. That’s something the researchers are looking into. “Targeting them might provide therapeutic benefits, but we’re not sure yet,” says Knott. Targeting these proteins could prevent tumor cells from exiting a secondary site and spreading further.
In past years, efforts have been made to treat tumors by using drugs called angiogenesis inhibitors that curb the formation of new blood vessels, as tumors need blood vessels to grow and spread. These drugs have not been as successful as hoped in patients, and one reason could be because vascular mimicry kicks in to help tumors get nutrients and oxygen, speculates Wagenblast. “Maybe by targeting angiogenesis and also vascular mimicry at the same time we might actually have a better benefit in the clinic in the long run,” he says.
The researchers are now examining what it takes for tumor cells that have exited from a primary tumor into the bloodstream to then get out of the bloodstream and colonize a new site in the body. “We’ve identified some interesting targets that we think seem to be key for this step,” Knott says.
Written By: Sandeep Ravindran, Science Writer | firstname.lastname@example.org | 516-367-8455
This work was supported by the Howard Hughes Medical Institute, the National Institutes of Health, Kathryn W. Davis, the Hope Funds for Cancer Research and the Boehringer Ingelheim Funds.
“A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis” appears online in Nature on Wednesday, April 8, 2015. The authors are: Elvin Wagenblast, Mar Soto, Sara Gutiérrez-Ángel, Christina A. Hartl, Annika L. Gable,Ashley R. Maceli, Nicolas Erard, Alissa M. Williams, Sun Y. Kim, Steffen Dickopf, J. Chuck Harrell, Andrew D. Smith, Charles M. Perou, John E. Wilkinson, Gregory J. Hannon & Simon R.V. Knott. The paper can be obtained online at: http://www.nature.com/nature/index.html
About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratory’s education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. For more information, visit www.cshl.edu